All In Biotech

Drug Trial Radar · NCT06638502

Safety of HRX215 in Patients After Minor and Major Liver Resection

Double-Blind, Randomized, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of HRX215 in Participants After Major Hepatectomy, Preceded by Two Open Pilot Parts in Participants After Minor and After Major Hepatectomy Due to Colon Carcinoma Metastases

Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

May 6, 2025

Primary completion

Jul 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
HepaRegeniX GmbHIndustry
Sponsor type
Industry
First posted
Oct 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if HRX215 is safe, tolerable and active in adults who have undergone liver resection due to colorectal carcinoma metastases. The objectives are: 1. to learn about the safety and tolerability of HRX215 2. to learn about how the body absorbs, distributes, and gets rid of HRX215. 3. to learn about clinical activity of HRX215 Researchers will compare HRX215 to a placebo (a look-alike substance that contains no drug) to investigate safety, tolerability and clinical activity in participants taking HRX215.

Conditions

  • Liver Resection
  • Colorectal Carcinoma Liver Metastases

Interventions

  • HRX215 capsulesDrug

    HRX215 250 mg orally twice daily for a total treatment duration of 28 days

  • Placebo capsulesDrug

    placebo matching appearance of HRX215, orally twice daily for a total treatment duration of 28 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Events (AEs) observedTime frame: 6 months
  2. HRX215 plasma levelsTime frame: 28 days

Locations

14 sites in 5 countries. Site status is shown where the registry gives one.

  • Johns Hopkins Hospital

    Baltimore, Maryland · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Duke Cancer Institute

    Durham, North Carolina · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • Centre Hospitalier Régional Universitaire de Lille (CHRU) Hôpital Claude Huriez

    Lille, France · Recruiting

  • Hôpital Paul-Brousse - Centre Hepato-Biliaire (CHB)

    Villejuif, France · Recruiting

  • Universitatsklinikum Essen

    Essen, Germany · Recruiting

  • Univ. Tuebingen - Universitaetsklinik fuer Allgemeine, Viszeral- und Transplantationschirurgie

    Tübingen, Germany · Recruiting

  • Rabin Medical Center

    Petah Tikva, Israel · Recruiting

  • Sheba Medical Center

    Ramat Gan, Israel · Recruiting

  • Tel-Aviv Sourasky MC

    Tel Aviv, Israel · Active not recruiting

  • Hospital Universitario La Paz

    Madrid, Spain · Recruiting

  • South Texas Accelerated Research Therapeutics Madrid - CIOCC - Universitario Sanchinarro

    Madrid, Spain · Recruiting

  • Consorci Hospital General Universitari de València

    Valencia, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.